Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Radicle Women's HealthTM: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes Among Women Experiencing Menopausal Symptoms

10. august 2026 opdateret af: Radicle Science

Radicle Women's HealthTM: A Randomized, Double-Blind, Placebo- Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes Among Women Experiencing Menopausal Symptoms

Radicle Women's HealthTM: A randomized, double-blind, placebo- controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related health outcomes among women experiencing menopausal symptoms.

Studieoversigt

Detaljeret beskrivelse

This is a randomized, double-blind, placebo-controlled study conducted with adult participants, residing in the United States. Eligible participants (1) are female, (2) aged 35-60, (3) currently experience menopausal symptoms, (4) have the opportunity for meaningful improvement (at least 30%) in their primary health outcome, and (5) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants that report a known cardiac dysfunction, liver or kidney disease may be excluded. Participants that report a known contraindication or with well-established, significant safety concerns due to illness will be excluded. Heavy drinkers and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Participants that report taking medications with a known contraindication or with well-established, significant safety concerns will be excluded. Self-reported data are collected electronically from eligible participants for 7 weeks. Participant reports of health indicators will be collected at enrollment and throughout the active period of study product usage. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

502

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Del Mar, California, Forenede Stater, 92014
        • Radicle Science Inc.

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ja

Beskrivelse

3.1 Inclusion

Participants must meet all the following criteria:

  • Adults, 35-60 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities

    • Assigned sex at birth is female
  • Experience at least two menopausal symptoms
  • Resides in the United States
  • Has the opportunity for at least 30% improvement in their primary health outcome
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

3.2 Exclusion

Individuals who report any of the following during screening may be excluded from participation:

  • Report being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid US shipping address and mobile phone number
  • Reports current enrollment in another clinical trial
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English at a 7th grade level
  • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
  • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.

    • NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
  • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.

    • Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
  • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products and/or pose a safety risk
  • Lack of reliable daily access to the internet
  • Reports surgical menopause/bilateral oophorectomy
  • Reports taking HRT or prescription menopausal products

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo Control
Fatigue Product Placebo Control
Participants will use their Fatigue Product Placebo Control as directed for a period of 6 weeks.
Eksperimentel: Active Product 1
Fatigue Active Product 1
Participants will use their Fatigue Active Product 1 as directed for a period of 6 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Chang in fatigue
Tidsramme: 7 weeks
Change in fatigue: Difference in rates of change over time in fatigue score as assessed by Patient Reported Outcome Measurement System (PROMIS) Fatigue 8A (scale 8-40; where higher scores correspond to more severe fatigue)
7 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Ændring i kognitiv funktion
Tidsramme: 7 uger
Ændring i kognitiv funktion: Forskel i ændringer over tid i kognitiv funktionsscore som vurderet af PROMIS kognitiv funktion 8A (skala 8-40; hvor lavere score svarer til dårligere kognitiv funktion)
7 uger
Ændring i følelser af angst
Tidsramme: 7 uger
Ændring i angstfølelse: Forskel mellem ændringer over tid i angstfølelsesscore som vurderet ved PROMIS Angst 8A (skala 8-40; med højere score svarende til mere alvorlig angst)
7 uger
Change in menopausal quality of life
Tidsramme: 7 weeks
Change in menopausal quality of life: Difference between rates of change over time in menopausal quality of life score as assessed by Menopause-specific Quality of Life Questionnaire (scale 1-8; where the higher scores correspond to worse menopausal quality of life)
7 weeks

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Minimal klinisk vigtig forskel (MCID) i kognitiv funktion
Tidsramme: 7 uger
Minimal klinisk vigtig forskel (MCID) i kognitiv funktion: Sandsynligheden for at opleve minimal klinisk vigtig forskel i kognitiv funktionsscore vurderet af PROMIS kognitiv funktion 8A (skala 8-40; hvor lavere score svarer til dårligere kognitiv funktion)
7 uger
Minimal klinisk vigtig forskel (MCID) i træthed
Tidsramme: 7 uger
Minimal klinisk vigtig forskel (MCID) i træthed: Sandsynligheden for at opleve minimal klinisk vigtig forskel i træthedsscore vurderet af PROMIS Fatigue 8A (skala 8-40; hvor højere score svarer til mere alvorlig træthed)
7 uger
Mindste klinisk vigtige forskel (MCID) i følelser af angst
Tidsramme: 7 uger
Mindste klinisk signifikante forskel (MCID) for angstfølelser: Sandsynlighed for at opleve mindste klinisk signifikante forskel i score for angstfølelser vurderet ved PROMIS Angst 8A (skala 8-40; hvor højere scorer svarer til mere alvorlig angst)
7 uger
Minimal clinically important difference (MCID) in menopausal quality of life
Tidsramme: 7 weeks
Minimal clinically important difference (MCID) in menopausal quality of life: Likelihood of experiencing minimal clinically important difference in menopausal quality of life score as assessed by Menopause-specific Quality of Life Questionnaire (scale 1-8; where the higher scores correspond to worse menopausal quality of life)
7 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Susan Hewlings, Radicle Science

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

7. maj 2026

Primær færdiggørelse (Faktiske)

5. august 2026

Studieafslutning (Faktiske)

5. august 2026

Datoer for studieregistrering

Først indsendt

1. maj 2026

Først indsendt, der opfyldte QC-kriterier

1. maj 2026

Først opslået (Faktiske)

7. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. august 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. august 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • RADX_P_2608_DIF

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Data will not be shared with researchers outside of Radicle Collaborators on this study.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner